I agree 100 percent I just can’t understand the discount to AVL.we spent far less to do two studies to AVL one.on crux investor Vince claims an expert team.they are as shady as they come in my opinion!
NTI Neurotech knocked back by FDA as agency declares target condition not rare enough for special status